Tegaserod for treating chronic constipation in elderly patients

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 309-313

  Baun, Ronald F ^a   Levy, Hedva Barenholtz ^b,c,d  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d NONE   (United States)

Author keywords

Constipation; Elderly; Tegaserod

Indexed keywords

TEGASEROD;

ADULT; AGED; AGING; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOWER ABDOMINAL PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; CHRONIC DISEASE; CONSTIPATION; GASTROINTESTINAL TRANSIT; HUMANS; INDOLES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 33847394536     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H220     Document Type: Article

References (13)

1. Bosshard W, Dreher R, Schnegg J, Bula C. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004;21:911-30.
2. Franklin RSM, Stratton MA. Constipation and bowel management. In: Delafunente JC, Stewart RB, eds. Therapeutics in the elderly. 3rd ed. Cincinnati, OH: Harvey Whitney Books, 2001:643-65.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130: 1480-91.
4. Locke GR, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology 2000;119:1761-6.
5. New Drug: Amitiza (lubiprostone). Pharmacist's letter/prescriber's letter 2006;22:220406.
6. Package insert. Zelnorm (tegaserod). East Hanover, NJ: Novartis Pharmaceuticals, August 2004.
7. Chapron DJ. Drug disposition and response. In: Delafunente JC, Stewart RB, eds. Therapeutics in the elderly. 3rd ed. Cincinnati, OH: Harvey Whitney Books, 2001:257-88.
8. Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Aliment Pharmacol Ther 2001;15:937-44.
9. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796-805.
10. Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362-72.
11. Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006; 4:605-13.
12. Data on file. East Hanover, NJ: Novartis Pharmaceuticals, December 2005.
13. Muller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006; 101:2558-69.